In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines

Cancer

Volumn 77, Issue 9, 1996, Pages 1862-1872

  Sokoloff, Mitchell H ^a   Tso, Cho Lea ^a   Kaboo, Randhir ^a   Taneja, Samir ^a   Pang, Shen ^a   DeKernion, Jean B ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cell adhesion molecules; cytokines; immunotherapy; prostate cancer; prostate specific antigen

Indexed keywords

CYTOKINE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER INVASION; CELL ADHESION; CELL LINE; CELL PROLIFERATION; CYTOSTASIS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TARGET CELL; TUMOR GROWTH;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CELL ADHESION MOLECULES; CELL LINE; COLLAGENASES; CYTOKINES; DIPEPTIDASES; DISEASE PROGRESSION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE CARBOXYPEPTIDASE II; GROWTH SUBSTANCES; HLA ANTIGENS; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; ONCOGENES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0029916720     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1862::AID-CNCR16>3.0.CO;2-Y     Document Type: Article

References (49)

1. Wingo PA, Tong T, Bolden BA. Cancer statistics, 1995. CA 1995;45:8-30.
2. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807-11.
3. Stamey TA, Yang N, Huy AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
4. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Campbell's Urology, 6th ed. Walsh P, Retik AB, Stamey TA, Vaughan ED, editors. Philadelphia: W.B. Saunders, 1992; 1159-221.
5. Ware JL. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metast Rev 1993;12:287-301.
6. Cohen, DW, Simak R, Fair WR, Melamed J, Scher HI, Cordon-Cardo, C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J Urol 1994;152:2120-4.
7. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
8. Sadasivan R, Morgan R, Jenning S, Austenfeld M, Van Veldhuizen P, Stephens R, et al. Overexpression of her-2/neu may be an indicator of poor prognosis in prostate. J Urol 1993;150:126-31.
9. Witkowski CM, Rabinovitz IR, Nagle RB, Affinito K-SD, Cress AE. Characterization of integrin subunits, cellular adhesion and tumorigenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993;119:637-44.
10. Dedhar D, Saulnier R, Nagle R, Overall CM. Specific alternation in the expression of α3β1 and α6β4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metast 1993;11:391-400.
11. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HF, Karthaus HF, Oosterhof G, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-33.
12. Giroldi LA, Schalken JA. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications. Cancer Metast Rev 1993;12:29-37.
13. Chi SG, deVere White, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: Frequently expressed transition mutations. J Natl Cancer Inst 1994;86:926-33.
14. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols S. Gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-69.
15. Foster CS, McLoughlin J, Bashir I, Abel PD. Markers of the metastatic phenotype in prostate cancer. Human Pathol 1992;23:381-94.
16. Myers C, Trepel J, Sartor O, Cooper M, Ranson M, Toko T, et al. Antigrowth factor strategies. Cancer 1993;71:1172-8.
17. Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, et al. Antitumor effects of analogs of LH-RH and somatostatin: Experimental and clinical studies. J Steroid Biochem Mol Biol 1990;37:1061-7.
18. Figlin RA, Pierce WC, Belldegrun A. Combination biologic therapy with interleukin-2 and interferon-alpha in the outpatient treatment of metastatic renal cell carcinoma. Semin Oncol 1993;20:11-5.
19. Carreno V, Mora I. Combination of recombinant interferons alpha and gamma in treatment of chronic hepatitis B. Lancet 1987;2:1086-9.
20. Fraker DL, Alexander HR. The use of tumour necrosis factor (TNF) in isolated perfusion: Results and side effects. The NCI results. Melanoma Res 1994;4(Suppl 1):27-9.
21. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80.
22. Marskovsky E, Chen W, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989;143:1210-4.
23. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W, et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA 1984;81:4917-21.
24. Trinchieri G. Biology of natural killer cells. Adv Immunol 1898;47:187-376.
25. Phillip R, Epstein LB. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 1989;323:86-9.
26. Greiner JW, Fisher PB, Pestka S, Schlom J. Differential effects of recombinant human leukocyte interferons on cell surface antigen expression. Cancer Res 1986;46:4984-90.
27. Sherwood ER, Ford TR, Lee C, Kozlowski JM. Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. J Biol Response Modif 1990;9:44-52.
28. van Moorselaar RJ, van Stratum P, Borm G, Debruyne FM, Schalken JA. Differential antiproliferative activities of alpha-and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. Prostate 1991;8:331-44.
29. Fruehauf JP, Myers CE, Sinha BK. Synergistic activity of suramin with tumor necrosis factor-α and doxorubicin on human prostate cancer lines. J Natl Cancer Inst 1990;82:1206-9.
30. Hathorn R, Tso CL, Kaboo R, Pang S, Figlin R, Sawyers C, et al. In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. Cancer 1994;74:1904-11.
31. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN. Variations in the number of peptide- MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 1995;154: 567-76.
32. Vignali DA. The interaction between CD4 and MHC class II molecules and its effect on T cell function. Behring Inst Mitteilungen 1994;94:133-47.
33. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-903.
34. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991;5:1921-30.
35. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-8.
36. Cole MD. The c-myc oncogene: Its role in transformation and differentiation. Annu Rev Genet 1986;20:361-84.
37. FitzGerald DJ, Pastan I. Expression of the interleukin 6 receptor and IL-6 in prostate carcinoma cells. Cancer Res 1009;50:7786-8.
38. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study. Human Pathol 1993;24:4-9.
39. Liotta L, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991;64:327-36.
40. Makgoba MW, Sanders ME, Ginther Luce GE, Gugel EA, Dustin ML, Springer TA, et al. Functional evidence that intracellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 1988;18:637-40.
41. Johnson JP, Stade BG, Riethmuller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 1989;86:641-4.
42. Albelda SM, Mette SA, Buck CA. Integrin distribution in malignant melanoma: Association of subunit with tumor progression. Cancer Res 1990;50:6757-64.
43. Bosco M, Chen C, Matsuura N, Takada Y, Zetter BR, Hemler ME. In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science 1991;251:1600-2.
44. Dedhar S, Saulnier R, Nagle R, Overall CM. Specific alterations in the expression of alpha 3-beta 1 and alpha 6-beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metast 1993;11391-400.
45. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-5.
46. Giroldi LA, Schalken JA. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications. Cancer Metast Rev 1993;12:29-37.
47. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB. Reduction of E-cadherin levels and deletion of the a-catenin gene in human prostate cancer cells. Cancer Res 1993;53: 3585-90.
48. Tjoa BA, Kranz DM. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: A model for peptide-mediated tumor rejection. Cancer Res 1994;54:204-8.
49. Van der Bruggen P, Van den Eynde B. Molecular definition of tumor antigens recognized by T lymphocytes. Curr Opin Immunol 1992;4:608-12.